When was Pyxis Oncology founded?

Pyxis Oncology was founded in 2019 and raised its 1st funding round within a year of its incorporation.

Where is Pyxis Oncology located?

Pyxis Oncology is headquartered in Boston, United States.

Who is the current CEO of Pyxis Oncology?

David Steinberg of Pyxis Oncology. They have also founded 1 company.

How many employees does Pyxis Oncology have?

As of Aug 31, 2026, the latest employee count at Pyxis Oncology is 66.

Is Pyxis Oncology a funded company?

Pyxis Oncology is a funded company, having raised a total of $174M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jul 17, 2019.

When was the latest funding round of Pyxis Oncology?

Pyxis Oncology's latest funding was a $***** Post IPO round on Feb 27, 2024, with participation from 5 investors.

Where does Pyxis Oncology rank among its competitors?

Pyxis Oncology ranks 34th amongst 3411 active competitors, of which 1135 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Pyxis Oncology?

Pyxis Oncology's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Pyxis Oncology - 2026 Company Profile, Team, Funding, Competitors & Financials

Pyxis Oncology is a public company based in Boston (United States), founded in 2019 by Shaan Gandhi, Thomas Gajewski, David Steinberg and John Flavin. It operates as a Developer of antibody therapeutics for treating cancer. Pyxis Oncology has raised $174M in funding from investors like RTW Investments, Arix Bioscience and Leaps by Bayer. The company has 3411 active competitors, including 1135 funded and 787 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of antibody therapeutics for treating cancer. The product pipeline includes PYX-201 that targets fibronectin, PYX-202 that targets tumor antigen, and PYX-203 for hematological cancer. The antibody is used for initiating the immune response in dysfunctional immune cells in the tumor microenvironment to treat cancer such as tumor antigen-specific tumor-infiltrating lymphocytes (TILs).

Website: pyxisoncology.com
Social
Email ID: *****@pyxisoncology.com

Key Metrics

Founded Year

2019

Location

Boston, United States

Stage

Public

Total Funding

$174M in 3 rounds

Latest Funding Round

Post IPO, Feb 27, 2024, $*****

Investors

RTW Investments & 24 more

Ranked

34^th among 3411 active competitors

Employee Count

66 as on Aug 31, 2026

Investment & Acquisitions

Apexigen

Similar Companies

BeiGene & 666 more

Exit Details

Public

View Pyxis Oncology's full profile

Pyxis Oncology is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
PYXIS ONCOLOGY, INC. CIN: 1782223 , United States, Active	Jun 10, 2018	$10M - $50M (As on Dec 31, 2025)	50 (As on Mar 31, 2024)	-
Pyxis Oncology, Inc. CIN: 83-1160910 , Belgium, Active	Dec 31, 2018	-	56 (As on Mar 31, 2022)	-
Apexigen, Inc. CIN: 1814140 , United States, Active		-	28 (As on Dec 31, 2022)	-

Pyxis Oncology got listed on Oct 01, 2021.

Click here to take a look at Pyxis Oncology's IPO in detail

Pyxis Oncology has raised a total funding of $174M over 3 rounds. Its first funding round was on Jul 17, 2019. Its latest funding round was a Post IPO round on Feb 27, 2024 for $*****. 5 investors participated in its latest round. Pyxis Oncology has 25 institutional investors.

Here is the list of recent funding rounds of Pyxis Oncology:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 27, 2024	9332381	Post IPO	4438694	1781864	2289022	1750909
Mar 05, 2021	7495812	Series B	4659115	6309145	5986180	RA Capital Management & 17 more
Jul 17, 2019	4906847	Series A	6742363	4646617	Leaps by Bayer	Ipsen & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of Pyxis Oncology's funding rounds and investors

The founders of Pyxis Oncology are Shaan Gandhi, Thomas Gajewski, David Steinberg and John Flavin. David Steinberg is the CEO of Pyxis Oncology.

Here are the details of Pyxis Oncology's key team members:

Shaan Gandhi: Co-Founder of Pyxis Oncology.
Thomas Gajewski: Co-Founder of Pyxis Oncology.
David Steinberg: Co-Founder & CEO of Pyxis Oncology.
John Flavin: Co-Founder of Pyxis Oncology.

View details of Pyxis Oncology's Founder profiles and Board Members

Pyxis Oncology's employee count trend

Pyxis Oncology has 66 employees as of Aug 26. Here is Pyxis Oncology's employee count trend over the years:

Uncover Pyxis Oncology's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Pyxis Oncology include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Pyxis Oncology, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Leaps by Bayer, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
34th	Pyxis Oncology 2019, Boston (United States), Public	Developer of antibody therapeutics for treating cancer	$174M	RTW Investments, BVF Partners & 23 others	67/100